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The history of COPD
Abstract: The evolution of knowledge concerning COPD and its components – emphysema, 
chronic bronchitis, and asthmatic bronchitis – covers 200 years. The stethoscope and spirometer 
became important early tools in diagnosis and assessment. Spirometry remains the most effective 
means of identiﬁ  cation and assessment of the course of COPD and responses to therapy, and 
is grossly underused for this purpose. Knowledge of the pathogenesis, course and prognosis, 
and new approaches to therapy have dramatically improved our understanding of this important 
clinical entity. Smoking cessation improves the early course of disease. Long-term oxygen 
improves the length and quality of life in selected patients with hypoxemia. Surgery beneﬁ  ts 
a select few. Today, COPD is a steadily growing global healthcare problem, with increasing 
morbidity and mortality. Early identiﬁ  cation and prevention, and treatment of emerging stages 
of disease through smoking cessation and a growing number of bronchoactive drugs promises 
to change the outcome.
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Introduction
Chronic obstructive pulmonary disease is ﬁ  nally gaining the attention needed to 
begin to solve this common problem. It is deﬁ  ned as chronic airﬂ  ow obstruction 
that is progressive and only partly reversible (Pauwels et al 2001; Global Initiative 
for Chronic Obstructive Lung Disease 2004). COPD includes chronic bronchitis, 
emphysema, and chronic asthmatic bronchitis (deﬁ  ned further below). Today, COPD 
is the fourth most common cause of death in the USA, and is the only disease state 
that is rising in morbidity and mortality amongst the top ﬁ  ve killers. It resulted in 
a $32.1 billion loss to the USA economy in direct and indirect costs in 2003, and 
by 2020 is expected to become the third most common cause of death (NHLBI 
Data Fact Sheet 2003). Approximately 16 million adult Americans have COPD. 
Probably an equal number have asymptomatic or even symptomatic disease but 
are not diagnosed or treated (Mannino et al 2000). Interest in COPD is a recent 
development and few know the origins of this interesting disease spectrum. This 
review offers a glimpse into the rich history in the development of our present 
understanding of COPD. 
Early historical landmarks
Some of the earliest references to the description of emphysema include: Bonet’s 
description of “voluminous lungs” in 1679 (Bonet 1679); Morgagni’s (1769) description 
of 19 cases in which the lungs were “turgid”, particularly from air; and Baille’s 
illustrations of the emphysematous lung, thought to be that of Samuel Johnson (Baillie 
1789; Bishop 1959).
The beginnings of our clinical understanding of the chronic bronchitis component 
of COPD can be traced to Badham (1814), who used the word catarrh to refer to the 
chronic cough and mucus hypersecretion that are cardinal symptoms. He described 
bronchiolitis and chronic bronchitis as disabling disorders (Badham 1814). International Journal of COPD 2006:1(1) 4
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The emphysema component of disease was beautifully 
described by Laënnec (1821) in his Treatise of diseases of 
the chest. Laënnec, a clinician, pathologist, and inventor 
of the stethoscope, did careful dissections of patients that 
he had studied during life. He recognized that emphysema 
lungs were hyperinﬂ  ated and did not empty well (Laënnec 
1821). 
In his A treatise on the diseases of the chest and on 
mediate auscultation (1837, p 81) Laënnec wrote on em-
physema:
The disease which I designate by this title is very little 
known and has not hitherto been correctly described by 
any author. I for a long time thought it very uncommon, 
because I had observed only a few cases of it: but since I 
have made use of the stethoscope, I have veriﬁ  ed its exist-
ence as well on the living as the dead subject, and am led 
to consider it as by no means infrequent. I consider many 
cases of asthma, usually deemed nervous, as depending on 
this cause. The chief reason of this affection having been so 
completely overlooked is, that it is in some sort merely the 
exaggeration of the natural condition of the viscus.
In this era, smoking was rare, but it is a fact that emphysema 
may occur in non-smokers, particularly with a familial 
predisposition or from environmental-provoking factors. 
Laënnec continued:
In opening the chest, it is not unusual to ﬁ  nd that the lungs 
do not collapse, but they ﬁ  ll up the cavity completely on 
each side of the heart. When experienced, this will appear 
full of air . . . . The bronchus of the trachea are often at the 
same time a good deal ﬁ  lled with mucous ﬂ  uid (Laënnec 
1821, p 89).
Thus Laënnec had described a combination of emphysema 
and chronic bronchitis.
John Hutchinson invented the spirometer in 1846 (Hutch-
inson 1846). The spirometer is key to the diagnosis and 
management of COPD, yet its use is still poorly applied to 
the diagnosis and management of COPD in most locations 
in the world today. Hutchinson’s instrument only measured 
vital capacity. It took another 100 years for Tiffeneau to add 
the concept of timed vital capacity as a measure of airﬂ  ow, 
for spirometry to become complete as a diagnostic instrument 
(Tiffeneau and Pinelli 1947).
Osler’s Principles and practices of medicine (1916) 
says little about emphysema. Osler believed emphy-
sema was caused by excessive pressure in the alveoli 
(Osler 1916), and reference to the spirometer cannot be 
found in this classic text. In 1912, another author did 
not mention spirometry, but shows a nice picture of the 
sphygmomanometer, invented by Rico Rossi in 1896, and 
excellent quality EKG strips are shown (Bovard 1912). This 
occured 50 years after Hutchinson’s invention. A textbook 
of Disease in the chest in 1918 makes only brief mention 
of spirometry with no illustrations (Norris and Landis 
1918).
Gaensler introduced the concept of the air velocity index 
based on Tiffeneau’s work and later the forced vital capacity, 
which is the foundation of the FEV1 and FEV1/FVC percent 
(Gaensler 1950, 1951).
In 1944, one of the great teachers of emphysema, Ronald 
Christie, suggested that “The diagnosis should be considered 
certain when dyspnea on exertion, of insidious onset, not 
due to bronchospasm, or left ventricular failure, appears in a 
patient who has some physical signs of emphysema together 
with chronic bronchitis and asthma” (Christie 1944, p 145). 
It is clear from this statement that Christie recognized the 
individual components of COPD and relied on the history 
and physical examination for his diagnosis. Oswald described 
the clinical features of 1000 cases of chronic bronchitis in 
1953 (Oswald et al 1953). 
Barach and Bickerman (1956) edited the ﬁ  rst compre-
hensive text book, Pulmonary emphysema, which nicely 
describes the treatment of the era. These two physicians 
were early champions of treatment for emphysema. 
Contributors to this book included Dayman, the ﬁ  rst to 
recognize the spirometric and ﬂ  ow volume patterns indica-
tive of dynamic expiratory airway collapse in emphysema; 
Dickerson Richards, Nobel Laureate, who wrote on the pul-
monary circulation and cor pulmonale; Reuben Cherniack, 
who described respiratory acidosis and has made major 
contributions to our understanding of the diagnosis and 
treatment of emphysema for over half a century; and 
Menelee and Callaway, who described pulmonary function 
tests in emphysema patients. In all, 17 leading clinicians 
and clinical scientists contributed to this classic volume 
of the 1950s. 
The ﬁ  rst edition of Hinshaw and Garland (1956) (now 
Murray and Nadel) Textbook of respiratory medicine shows 
a nice picture of a Collins 13.5 liter recording spirometer, 
and shows capacity spirograms that demonstrate airﬂ  ow 
limitation in emphysema.
Deﬁ  nitions 
Two landmark meetings: The CIBA Guest Symposium in 
1959 (Ciba Guest Symposium 1959; Donald 1971) and International Journal of COPD 2006:1(1) 5
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the American Thoracic Society Committee on Diagnostic 
Standards in 1962 deﬁ  ned the components of COPD, which 
are the foundation for our deﬁ  nitions today (Committee 
on Diagnostic Standards for Nontuberculous Respiratory 
Diseases 1962). The American Thoracic Society (ATS) de-
ﬁ  ned chronic bronchitis in clinical terms including chronic 
cough lasting at least three months for at least two years. 
By contrast, the ATS deﬁ  ned emphysema in anatomic terms 
of enlarged alveolar spaces and loss of alveolar walls. Nei-
ther deﬁ  nition used any physiologic criteria. Asthma was 
described as a state of airway hyperresponsiveness to a 
variety of stimuli. Asthmatic bronchitis was considered an 
overlapping condition (Committee on Diagnostic Standards 
for Nontuberculous Respiratory Diseases 1962). (The author 
had the privilege of attending the deliberations of the ATS 
committee as a Resident in Medicine in 1962 in Memphis 
Tennessee during the time of the annual VA-Armed Forces 
Annual Conference on the Treatment of Tuberculosis.) 
Many other attempts to deﬁ  ne COPD have not improved on 
these basic deﬁ  nitions, except that COPD is now deﬁ  ned in 
functional terms. 
Other acronyms that predated the COPD designation 
were chronic obstructive bronchopulmonary disease, 
chronic airflow obstruction, chronic obstructive lung 
disease, nonspeciﬁ  c chronic pulmonary disease, and dif-
fuse obstructive pulmonary syndrome. William Briscoe 
is believed to be the ﬁ  rst person to use the term COPD in 
discussion at the 9th Aspen Emphysema Conference. This 
term became established and today we refer to COPD as 
the designation of this growing health problem (Briscoe 
and Nash 1965).
Pathology
In the past 50 years, the pathology of emphysema and other 
components of COPD have ﬁ  lled textbooks (Reid 1967; 
Heard 1969; Thurlbeck 1976). Loss of alveolar walls (em-
physema), mucous gland hyperplasia (Reid index) in large 
conducting airways (Reid 1960), and bronchiolitis with 
ﬁ  brosis have been extensively documented and illustrated. 
Thurlbeck’s book (1976) cites Jethro Gough and his ﬁ  rst use 
of whole lung thin sections to illustrate the various types of 
emphysema (Gough 1952; Thurlbeck 1976). 
The Dutch hypothesis and British hypothesis in 
pathogenesis were early basic concepts. The Dutch 
hypothesis presented the concept of genetically deter-
mined bronchial hyperreactivity in COPD (Orie and Sluiter 
1960). The British hypothesis proposed that repeated chest 
infections and air pollution contributed to the pathogenesis of 
chronic bronchitis (Stuart-Harris et al 1953; Scadding 1959). 
Both hypotheses are probably correct, and both bronchial 
hyperreactivity and chest infections plus irritant exposure 
are important in pathogenesis.
Experimental emphysema
Many disease models have yielded clues to cause, patho-
physiology, clinical manifestations, and therapeutic targets. 
Early attempts to produce experimental emphysema used 
obstructive devices placed in the major airways or trachea 
to attempt to reproduce hyperinﬂ  ation. The author spent a 
research summer employing the use of a venturi device (that 
had greater expiratory than inspiratory resistance) placed in 
the trachea of dogs. This study did not produce hyperinﬂ  a-
tion or emphysema. In fact the dogs developed reduced 
functional residual capacity with the tracheal obstruction, 
a fact of tracheal obstruction that was not known by this 
naïve student investigator. A presentation on experimental 
emphysema at the First Aspen Emphysema Conference in 
1958 documents this work and that of earlier investigators 
(Eiseman et al 1959).
The first credible production of emphysema was
by Gross in 1964, who instilled pancreatic extracts (papain) 
into the airways of guinea pigs to cause destruction of 
alveoli and hyperinﬂ  ation (Gross et al 1964). This was 
somewhat of a fortuitous discovery, since he was not trying 
to produce emphysema, but was hoping to determine the 
effect of papain on the ﬁ  brosis associated with experimen-
tal silicosis that he was studying. Gross’s work produced 
emphysema, due to proteolytic damage of elastin and thus 
was the forerunner of the protease – antiprotease therapy 
of the pathogenesis, as described by Laurel and Erickson 
(1963) in Sweden with alpha-one-antitrypsin deﬁ  ciency 
and emphysema. Other investigations also used elastases 
to produce experimental emphysema (Snider and Sherter 
1977). Many genetic, infectious, and immunologic models 
in small animals followed and continue to be investigated 
at the present time. A recent model employing methylpred-
nisolone to produce emphysema in rats induces matrix met-
alloproteinase and can be prevented by a metal proteinase 
inhibitor (Choe et al 2003). The concept that emphysema 
is an autoimmune vascular disease has been offered as 
one pathway in pathogenesis (Voelkel and Taraseviciene-
Stewart 2005). Studies in experimental emphysema, though 
possibly species speciﬁ  c, are useful in suggesting new 
therapeutic targets. International Journal of COPD 2006:1(1) 6
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The Aspen emphysema conferences
The growing problem of emphysema and related disorders 
was the stimulus for a planned series of emphysema confer-
ences held annually in Aspen, Colorado, beginning in 1958 
(Mitchell 1959). Roger S Mitchell and his colleagues, Giles 
F Filley, and John R “Jack” Durrance, were the driving 
force that launched these landmark conferences. Financial 
support came from the Department of Medicine of the 
University of Colorado pulmonary division and local and 
national tuberculosis associations. The major topics of the 
ﬁ  rst conference included the state-of-the-art understanding 
of anatomy, pathology, physiology, experimental studies, 
natural history, unusual forms, and allergy in relation to 
emphysema. JH McLean’s pioneering work on bronchiolitis 
was and remains a highlight. Liebow described vascular 
injury including capillary loss in emphysema, and Loosli 
described loss of elastic ﬁ  bers. Pierce discussed lung elas-
tin and collagen, and Brantigan’s lung volume reduction 
surgery was discussed as an innovative method of treating 
a small number of selected patients with advanced emphy-
sema. Subsequent conferences discussed certain collateral 
subjects including asthma, the environment, and the lung 
and pulmonary circulation. 
The conferences were intended to conclude after the 
1964 meeting. However, the author, now on the junior 
faculty of the pulmonary division, and his colleagues 
had a burning desire to have one “last” conference 
on the treatment of COPD. Somewhat magically, the 
Chronic Respiratory Disease Branch of the Public Health 
Service generously supported the 8th Aspen Emphysema 
Conference. It presented new concepts in the management 
of acute respiratory failure, home care and rehabilitation, 
pharmacologic agents in current use, and the new concept 
of ambulatory oxygen in the treatment of advanced COPD. 
Surgical resection was again discussed by Brantigan, 
but now with caution because of high perioperative 
mortality. 
This conference may have been the “tipping point” in the 
establishment of comprehensive treatment for COPD (Petty 
1967). Because of the success of the 8th conference, the 9th, 
10th, and 11th conferences were held annually at the same 
venue. These three conferences dealt with the mushrooming 
advances in research in COPD during that era. At the 9th 
conference Ben Burrows and Charles Fletcher presented 
their concept of “The bronchial and emphysematous types 
of chronic obstructive lung disease in London and Chicago”, 
pointing out that the same disease spectrum was found on 
both sides of the Atlantic. This work was also published 
elsewhere (Burrows et al 1966). Fletcher gave his initial 
ﬁ  ndings on “Prognosis in chronic bronchitis”. 
Subsequent conferences, namely the 12th, 22nd, 26th, 
and 44th conferences, have documented great progress in 
our understanding of all aspects of COPD and its treatment. 
The 48th was the most recent Thomas L Petty Aspen Lung 
Conference (its present name) to discuss COPD and related 
disorders, and began with a clinical theme emphasizing the 
different COPD phenotypes. 
Clinical–pathological correlations
Roger S Mitchell and colleagues began a series of studies 
of the pathology of alveolar and airways damage in 
patients, participating in an early emphysema registry, who 
later died and had autopsies at the University of Colorado 
Medical Center. The focus was mostly on mucous gland 
hyperplasia and inﬂ  ammation of large conducting airways 
and loss of alveolar walls (Mitchell et al 1966, 1968). 
The lesion of bronchiolitis (small airways) inﬂ  amma-
tion was also described by Mitchell et al (1976) in early 
reports.
Structure/structure–function 
relations in COPD
Also using an artiﬁ  cial thorax to ventilate fresh post-mortem 
lungs, the Denver Group began a series of systematic studies 
that were designed to evaluate structure/function relation-
ships and the major lesions associated with COPD, loss of 
alveolar walls (emphysema), and mucous gland hyperplasia 
(chronic bronchitis) (Petty et al 1965). By ventilating a 
whole fresh excised human lung that had been obtained at 
autopsy, and occasionally was available at the time of dona-
tion of organs for transplantation, it was possible to study 
lung mechanics both from lungs in subjects with no clinical 
lung disease and in patients with various stages of COPD. 
The investigators could measure many physiologic indices, 
including FEV1, FVC, maximum mid-expiratory flow, 
residual volume, and nitrogen washout tests, to study the 
physiologic expression of lesions of the small airways (Petty 
et al 1980, 1984, 1987). The measurement of the post-mortem 
FEV1 bore a close correlation with the FEV1 measured during 
life in the majority of patients (r=0.891), adjusted for both 
lungs (Petty et al 1965). Progressive grades of emphysema 
were associated with reductions in FEV1. The lesion of 
mucous gland hyperplasia (ie, the Reid index; Reid 1960) 
did not have a close correlation with airﬂ  ow measurements. International Journal of COPD 2006:1(1) 7
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Dynamic airway collapse of the central airways was related 
to reductions in FEV1.
Accurate smoking histories were available in another 
series of 154 autopsied patients. Lesions of mucous gland 
hyperplasia and emphysema were found in nearly 50% of 
the smokers. Eight non-smokers also had these lesions (Petty 
et al 1967). Whether or not these patients had other risk fac-
tors for the development of the pathologic lesions associated 
with COPD is not known. This study was performed before 
the era of understanding the contributions of small airway 
pathology to airﬂ  ow obstruction.
The landmark study by Hogg et al (1968) ushered in the 
era of small airways disease. To learn whether or not the 
nitrogen washout test would identify the lesions of small 
airways disease, the Denver Group performed additional 
studies on this and other tests that purported to identify early 
lesions in patients with COPD with emphysema and on the 
pathology of small airways (Petty et al 1980, 1984, 1987). 
Cosio et al (1978) provided his grading photomicrographs 
of mild, moderate, and severe inﬂ  ammation and mild, 
moderate, and severe ﬁ  brosis of small airways. Emphysema 
was found to relate to a reduction in elastic recoil and in the 
percentage of the predicted FEV1 (Silvers et al 1974, 1980; 
Petty et al 1984). Elastic recoil was inversely proportional 
to the closing capacity and the slope of phase III disease 
(Petty et al 1980). In addition, the maximum expiratory 
ﬂ  ow volume was not related to emphysema (Petty 1984). 
Fairly good correlations were found among the FEV1, 
FVC, and static lung recoil at 70% of inﬂ  ation (Petty et al 
1984). Increased lung size (TLC and FR) were related to 
loss of elastic recoils, but not to airﬂ  ow obstruction (Petty 
et al 1987).
Numerous key studies initiated by the Montreal group 
(Cosio, Saetta, Angine, and others) have shown that reduced 
alveolar attachments, elastic recoil, and alveolar fenestrae 
are all interrelated and associated with smoking. Reduced 
elastic recoil is a major factor in the development of airﬂ  ow 
limitation (Saetta, Shiner, et al 1985; Cosio et al 1986; Saetta 
2001). 
During the course of these studies, several unu-
sual patients with COPD were encountered, including a 
29-year-old man who died of end-stage emphysema and 
a 19-year-old man who had severe pulmonary hypertension, 
emphysema, and marked narrowing of the conducting 
airways of the lungs. The Denver studies also identiﬁ  ed the 
lesion of duct ectasia (ie, an unwinding of alveolar ducts due 
to loss of elastic recoil) in nonsymptomatic aged individuals 
(Ryan et al 1965).
The natural history of COPD
Charles Fletcher devoted his life to the study of the natural 
history of COPD (Fletcher et al 1976). He recognized the 
risks of smoking and the accelerated rate of decline in 
FEV1 in susceptible smokers on the pathway to disabling 
symptoms (Fletcher et al 1976). He and his colleagues 
recognized that stopping smoking would retard the rate of 
FEV1 decline to that approaching the rates of reduction in 
age-related non-smokers (Peto et al 1983). This established 
the scientiﬁ  c foundation for smoking cessation in every 
stage of disease (see Lung Health Study) (Anthonisen et al 
1994, 2005).
Burrows and Earle described the course and prognosis 
of 200 patients with COPD in his classic study in Chicago 
(Burrows and Earle 1969). Later, when observing similar 
patients in his lifelong study of prognosis of emphysema in 
a large population in Tucson, Arizona, he recognized that 
patients with a low FEV1/FVC percentage predicted the onset 
of rapid decline in FEV1 over time. Patients with the most 
rapid rate of decline had the worst prognosis. He termed this 
phenomenon as “The Horse Racing Effect” (Burrows et al 
1987). The discovery also established the importance of early 
identiﬁ  cation and intervention (see section titled The NLHEP 
and GOLD initiatives).
The natural history of COPD begins with complex 
biochemical and cellular events in the small airways and sur-
rounding alveoli. Early in the course, damage to the structure 
leads to a loss of elastic recoil (Saetta, Ghezzo, et al 1985; 
Saetta, Shiner, et al 1985; Petty et al 1987). The lungs begin 
to increase in size, and the FVC increases (Petty et al 1987). 
This results in early physiologic alterations that can be readily 
identiﬁ  ed by simple spirometry (Burrows et al 1987). By the 
time clinical signs are present, COPD is often in a moderate-
to-advanced stage (Mannino et al 2000).
Pathologic evidence of emphysema can be derived 
from CT studies or from resectional material, such as when 
solitary nodules are removed (Cosio et al 1978, 1986). The 
most practical way to diagnose and to access the functional 
progress of COPD is by spirometry. The initial smoking-
induced injury to the human lungs appears to be in the 
small conducting air passages and surrounding alveoli. 
When alveoli become damaged or lost, the elastic support-
ing structure of the lung is reduced (Figures 1 and 2). This 
results in both a loss of elastic recoil and in increased airways International Journal of COPD 2006:1(1) 8
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resistance since airways are no longer tethered by the radial 
traction forces of the surrounding alveolar attachments. Mural 
inﬂ  ammation of small airways and airways remodeling also 
reduce the airway lumen.
Thus, the interrelated causes of airﬂ  ow obstruction in 
COPD patients include a combination of airways inﬂ  am-
mation and remodeling, bronchospasm, mucous hyper-
secretion, and loss of elastic recoil. There is a complex 
interrelationship among these phenomena, which results 
in the progressive reduction in expiratory airﬂ  ow as judged 
by the FEV1.
It deserves emphasis that early stages of emphysema are 
characterized by both hyperinﬂ  ation and an increased FVC 
(Burrows et al 1987; Petty et al 1987). This is the reason why 
the FEV1/FVC ratio is such a sensitive test for early stages 
of airﬂ  ow obstruction. An FEV1/FVC of <70% heralds the 
onset of rapid declines in FEV1 over the course of a 10-year 
period (Burrows et al 1987). The time course of these changes 
in alveoli and small airways is illustrated in Figure 3. Thirty 
or more years of progressive loss in airﬂ  ow may take place 
before the threshold to dyspnea on exertion occurs, which 
is usually at <1.5 L/s and may be as low as 1.0 L/s in smaller 
persons.
Treatment of COPD: past, present, 
and future
Over 47 years ago, when the author graduated from medical 
school, the only therapies for COPD were antibiotics for 
pneumonia, potassium iodide used as a mucus thinner, and 
combination products containing ephedrine, a small amount 
of theophylline, and a minor amount of sedative to deal with 
the side effects of ephedrine. Inhaled isoproterenol began to 
be used in the early 1960s. In that era, oxygen was consid-
ered contraindicated, and exercise was prohibited for fear of 
straining the right heart. Corticosteroids were almost never 
used, even in cases of exacerbations of COPD. One paper in 
the early 1960s by Noehren, offered new hope that at least 
some treatments might be beneﬁ  cial in emphysema. Both 
medical and surgical approaches to therapy were described 
(Noehren 1962).
Management of acute respiratory failure
Beginning in the early 1960s, patients with COPD began 
to be saved with the use of mechanical ventilators for the 
management of acute respiratory failure (Petty 1971). The 
development of systematic therapy for nonhospitalized 
patients can be traced to the 8th Aspen Emphysema Confer-
ence, which was held in June 1965 (Petty 1967). This was 
the only Aspen Emphysema Conference devoted entirely to 
treatment. The Denver Group presented their ﬁ  rst observa-
tions on ambulatory oxygen at the conference. The many 
topics discussed by clinicians and scientists at the conference 
included principles of pulmonary rehabilitation, the treat-
ment of cor pulmonale, home care for chronic pulmonary 
insufﬁ  ciency, and surgical treatments for emphysema. The 
subsequent 22nd, 26th, and 42nd Aspen Lung Conferences 
also had COPD as their theme.
Long-term oxygen therapy (LTOT)
In the ﬁ  rst Denver studies of ambulatory oxygen, patients 
with chronic stable hypoxemia experienced remarkable 
Figure 1 Small respiratory bronchiole with surrounding alveolar attachments. 
These alveolar attachments serve to tether small airways. Source: Petty T. 2002. 
COPD in perspective. Chest, 121 Suppl:116S–120S. Reproduced with permission 
from The American College of Chest Physicians.
Decreased  elasticity
of supporting structure
Plugging, inflammatory
narrowing, and
obliteration of
small airways
Destruction of
peribronchiolar support
Figure 2  A drawing describing the mechanisms of airﬂ  ow obstruction due to 
the losss of elastic recoil and airway narrowing. Source: Petty T. 2002. COPD in 
perspective. Chest, 121 Suppl:116S–120S. Reproduced with permission from The 
American College of Chest Physicians.International Journal of COPD 2006:1(1) 9
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reductions in pulmonary hypertension and erythrocytosis, 
along with a great increase in exercise tolerance (Levine et al 
1967). This and several other early pilot studies resulted in 
the design of the Nocturnal Oxygen Therapy Trial (Nocturnal 
Oxygen Therapy Trial Group 1980). The Medical Research 
Council Clinic Trial compared 15 h of oxygen with air breath-
ing (The Medical Research Council Working Party 1981). 
Together, these two studies established the scientiﬁ  c basis of 
long-term oxygen therapy, which is the only treatment that 
has been proven to alter the course of disease and prognosis 
of patients with advanced COPD (Petty 1990).
Pulmonary rehabilitation
Pulmonary rehabilitation evolved from that earlier era (Petty 
et al 1969; Petty 1993). The systematic use of drugs to restore 
pulmonary function, including bronchoactive drugs (ie, 
bronchodilators and corticosteroids) began to gain popular-
ity in the 1990s. An emphasis on the importance of smoking 
cessation became a feature of treatment in the 1990s.
Surgery
The technique of Lung Volume Reduction Surgery (LVRS), 
originally introduced by Brantigan and Mueller (1957) and 
was resurrected by Cooper and others in the 1990s (Cooper 
et al 1996). A randomized controlled clinical trial completed 
in 2003 showed no reduction in mortality but an improved 
quality of life in a subset of surgical patients (National 
Emphysema Treatment Trial Group 2003). A subset of 
patients with primarily upper lobe disease and poor exercise 
tolerance following pulmonary rehabilitation did have a 
small but signiﬁ  cant survival beneﬁ  t (National Emphysema 
Treatment Trial Group 2003).
Lung transplantation is established for a small number 
of patients, due to the lack of organ availability (Studer et al 
2004). Long-term survival for lung transplantation is limited 
by a high index of organ rejection and bronchiolitis obliterans 
(Studer et al 2004).
Corticosteroids and bronchodilators
Five studies (Paggiaro et al 1998; Pauwels et al 1999; Vestbo 
et al 1999; Burge et al 2000; The Lung Health Study Research 
Group 2000), which were conducted in the 1990s on therapy 
with inhaled corticosteroids have resulted in interesting 
and somewhat conﬂ  icting conclusions. Although a small 
subset of patients has a slight step-up in FEV1 following the 
administration of inhaled corticosteroids, the rate of decline 
in FEV1 was not retarded in any of the studies completed 
thus far. However, symptoms of cough, expectoration, and 
exacerbations of chronic bronchitis were signiﬁ  cantly re-
duced in patients in the treatment groups compared with 
those in the placebo group. Symptomatic beneﬁ  ts need to 
be weighed against the possibility of systemic side effects 
(eg, reduced bone density) if inhaled corticosteroids are to 
be used in the long term (The Lung Health Study Research 
Group 2000).
Improved survival in COPD using a combination of ﬂ  uti-
casone propionate and salmeterol has been suggested in case 
controlled studies (Soriano et al 2002; Sin and Man 2003). 
Prospective randomized controlled studies are currently in 
progress to attempt to conﬁ  rm these ﬁ  ndings.
COPD as a systemic disease
It has been learned that patients with only mild stages of 
COPD may have signiﬁ  cant cardiovascular physiologic 
impairments. These individuals cannot achieve maximum 
oxygen uptake or a maximum heart rate. Their exercise 
performance is limited and is likely due to physical de-
conditioning, even in patients with only mild degrees of 
airﬂ  ow obstruction and without hypoxemia (Carter et al 
1993). We must now recognize COPD as a systemic disease 
and start to understand the metabolic and musculoskeletal 
implications of this generalized process (Schols et al 1996, 
1998). COPD has been recognized as a risk factor for car-
diovascular morbidity and mortality (Sin and Man 2005). 
Thus corticosteroids may (or may not) have a beneﬁ  cial 
role on the underlying systemic nature of COPD. Obviously 
this is an area that requires intense factor investigation. 
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Figure 3 The natural history of COPD. Source: Petty T. 2002. COPD in 
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The pathogenesis of pulmonary hypertension in COPD and 
its treatment also remain a huge challenge (Higgenbottom 
2005). We need to learn much more about the molecular 
genetics of COPD (Sanford et al 1997). Why do only
15%–20% of smokers develop airﬂ  ow obstruction (Sanford 
et al 1997)?
The Lung Health Study
Following a preliminary meeting organized by the author 
in 1982 during his presidency of the American College of 
Chest Physicians and attended by many experts who were 
both for or against studies of early identiﬁ  cation, the Lung 
Health Study was planned and implemented by the Lung 
Division of the National Heart, Lung, and Blood Institute 
(NHLBI). In all 10 centers, 5887 volunteers were enrolled 
who were heavy smokers between the ages of 35 and 60, 
and who had any degree of airﬂ  ow obstruction identiﬁ  ed 
at baseline screening (Anthonisen et al 1994). Subjects 
were randomized to receive special care or usual care 
in a 2:1 ratio. Half of the subjects randomized to special 
care received ipratropium bromide and the other half an 
identical placebo inhaler. The initial report of outcome 
showed that 22% of patients who received special care 
stopped smoking as part of the study, compared with 5% 
in the usual care group. Patients who succeeded in stop-
ping had a small improvement in FEV1 initially, followed 
by a slow decline up to ﬁ  ve years of follow-up (Figure 4). 
Ipratropium did not improve baseline lung function, but 
did increase airﬂ  ow on each day that it was tested over the 
course of the study.
The most common cause of death was lung cancer (57), 
compared with 37 cardiac deaths and 55 deaths from all 
other cancers (N=149). At a 14.5-year follow-up, the most 
common cause of death remained lung cancer (33%), with 
cardiovascular deaths the second most common cause of 
death (22%). Coronary artery disease was also a common 
cause of death but the death records had an overlap with the 
designation of cardiovascular deaths. Seven point 8 percent 
(7.8%) died of nonmalignant respiratory disease. Two point 
three percent (2.3%) died of unknown causes. This powerful 
study showed conclusively that stopping smoking in middle 
age (Anthonisen et al 2005) was associated with a much better 
survival than in patients who continued to smoke. This study 
and others form the scientiﬁ  c basis for early identiﬁ  cation 
of COPD and related disorders, the most common of which 
is lung cancer. 
The NLHEP and GOLD initiatives
Following a preliminary planning meeting in 1993 and a 
comprehensive workshop on COPD sponsored by the Lung 
Division of the NHLBI, the need for a new national health 
initiative for the early diagnosis, treatment, and research 
in COPD was launched in a major publication (Petty and 
Weinmann 1997) and later on gained full support in CHEST 
(Petty 1998). Soon thereafter, the National Lung Health 
Education Program (NLHEP) was founded by the author, 
who was its ﬁ  rst chairman. Initial NIH support was sup-
plemented by unrestricted grants from the pharmaceutical 
industry. All major societies with a stake in COPD sent 
representatives to the biennial board of directors meeting 
held at the times of the American College of Chest Physi-
cians and ATS. Numerous publications and recommendations 
followed. The most notable was the consensus’s statement 
of the NLHEP, which recommended the spirometric testing 
of all smokers aged 45 or older and anyone with chronic 
cough, dyspnea on exertion, mucus hypersecretion, or wheeze 
(Ferguson et al 2000). This helped promote the development 
of accurate and inexpensive ofﬁ  ce spirometers for widespread 
use. In 2004, the NLHEP’s administrative functions were 
Figure 4 Mean post-bronchodilator forced expiratory volume at 1 second (FEV1) 
for participants in the smoking intervention and placebo group who were sustained 
quitters (O) and continuing smokers ( ). The two curves diverge sharply after 
baseline. Source:  Anthonisen NR, Connett JE, Kiley JP. 1994. Effects of smok-
ing intervention and the use of an inhaled anticholinergic bronchodilator on the 
rate of decline of FEV1. The Lung Health Study. JAMA, 272:1497–505. Copyright 
© 2004.  American Medical Association.  All rights reserved. Reproduced with 
permission from AMA.
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transferred to the American Association for Respiratory Care 
(AARC), and a new Chairman, Professor Dennis Doherty of 
the University of Kentucky, succeed the author, who remains 
Chairman Emeritus and is still actively involved (Petty and 
Doherty 2004). 
In 2001, the Global Initiative of Obstructive Lung Disease 
(GOLD) was launched by the WHO and NHLBI (Pauwels 
et al 2001; Global Initiative for Chronic Obstructive Lung 
Disease 2004). International in scope, GOLD offered a new 
classiﬁ  cation of the severity of COPD, which is now ac-
cepted by most societies and organizations. Together, the 
NLHEP and GOLD will continue to raise awareness of the 
importance of COPD and promote early identiﬁ  cation and 
intervention.
Recent biologic studies and 
therapeutic targets
The pathogenesis of COPD is complex and involves 
multiple mechanisms. The bottom line of these processes 
is inﬂ  ammatory damage of the conducting airways and 
vascular damage of the alveolar surface of the lung, which 
constitutes the air–blood interface. Capillary damage leads 
to loss of both alveolar walls and reduced elastic recoil. 
Inﬂ  ammatory obstruction of small airways contributes to 
airﬂ  ow obstruction; the loss of alveolar walls and airﬂ  ow 
obstruction (as Laënnec ﬁ  rst described) are part and parcel 
of the pathogenesis.
The inflammatory process of COPD is initiated by 
inhalation of noxious gases in cigarette smoke and in the 
environment. All airways, including the central airways, 
become inﬂ  amed, which results in mucous gland hyperplasia 
and hypersecretion. Macrophages and CD8 cells are the 
prime cellular mediators, which include leukotriene B4, 
interleukin-8, and tumor necrosis factor (TNF) (Barnes 
2000). Thus, the inflammatory processes of COPD are 
markedly different from those of asthma. Inﬂ  ammation 
in asthma consists of more corticosteroid-responsive cells 
and mediators, such as mast cell-activated eosinophils, 
T-helper type 2 lymphocytes (CD4 phenotype), and a 
number of cytokines whose production is decreased by use 
of corticosteroids. This may explain, at least in part, why 
patients with COPD are not nearly as responsive as patients 
with asthma to both inhaled and systemic steroids.
The protease–antiprotease imbalance is certainly true 
in the alpha-1-antitrypsin deﬁ  ciency state. Matrix metal-
loproteinases, collagenases, and other tissue-degrading 
enzymes are released from macrophages and neutrophils. 
An oxidant–antioxidant imbalance also exists in small 
airways and at the air–blood interface. How this can be 
dealt with therapeutically remains a challenge. Potentially, 
many other mechanisms (including processes that trigger 
mucus hypersecretion or cause dysfunction) and inhibition 
of growth factors (such as vascular endothelial growth factor 
at a reduced level) result in premature apoptosis of capil-
laries and the alveolar walls they nourish (Kasahara 2001). 
Phosphodiester 4 inhibitors are a new class of drugs that may 
oppose or otherwise modify the basic inﬂ  ammatory processes 
of the small and large airways. Speciﬁ  c cytokine antagonists 
(eg, 1, 2, and 3) on TNF2 inhibitors are the subject of current 
investigations (Barnes 2000). Systemic clinical approaches to 
patients with COPD and cardiovascular disease are emerging 
(Soriano et al 2002; Rennard 2005; Sin and Man 2005). All 
of this new knowledge about the pathogenesis of emphysema 
and related airway inﬂ  ammation promises new therapeutic 
targets for the future.
Summary
The evolution of our understanding of emphysema and 
chronic bronchitis covers nearly four centuries. Anato-
mists, clinical scientists from many disciplines, and clini-
cians have contributed to the knowledge that an attack on 
alveoli and both large and small airways contribute to the 
emergence of chronic and ultimately irreversible airﬂ  ow 
limitation, due to loss of elastic recoil and increase in 
airﬂ  ow resistance through the complex conducting system 
of the lungs.
Dyspnea is due primarily to abnormal lung and thoracic 
mechanics and the increased work of breathing. Cough and 
mucus hypersecretion are due to inﬂ  ammation, mucous gland 
hyperplasia, and goblet cell hyperplasia. One or more host 
factors are involved in many patients, and family clustering 
may go beyond alpha-one-antitrypsin deﬁ  ciency. COPD must 
be considered a systemic disease. 
Treatment requires an elimination of smoking and other 
irritants in the environment. Such measures forestall or pre-
vent the premature loss of ventilatory function and loss of 
blood gas homeostasis. 
Treatment of symptomatic disease, beyond smoking 
cessation requires the use of bronchodilators and prob-
ably corticosteroids. Pulmonary rehabilitation and oxygen 
improve the quality and length of life in selected patients. 
Lung volume reduction surgery improves lung mechanics and 
reduces dyspnea by improving elastic recoil, which affects 
both airﬂ  ow and perfusion, thus ameliorating gas exchange International Journal of COPD 2006:1(1) 12
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abnormalities in selected patients. Lung transplantation helps 
a few patients.
The future requires early identiﬁ  cation and intervention 
in the basic disease processes. Spirometry must emerge as 
the fundamental way to diagnose and monitor responses to 
therapy. It must be employed by all who care for patients 
with COPD. New therapies must reduce both alveolar 
damage and inﬂ  ammation of the airways. The future for 
COPD science and improved prevention and patient care 
appears bright.
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